Janux Therapeutics (JANX) Competitors $25.15 -0.46 (-1.80%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$25.42 +0.28 (+1.09%) As of 07/11/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. NUVL, LNTH, TLX, AXSM, CRSP, ADMA, PCVX, RYTM, CYTK, and KRYSShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), ADMA Biologics (ADMA), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Its Competitors Nuvalent Lantheus Telix Pharmaceuticals Axsome Therapeutics CRISPR Therapeutics ADMA Biologics Vaxcyte Rhythm Pharmaceuticals Cytokinetics Krystal Biotech Nuvalent (NASDAQ:NUVL) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Is NUVL or JANX more profitable? Janux Therapeutics' return on equity of -9.29% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -31.35% -29.27% Janux Therapeutics N/A -9.29%-8.89% Do institutionals & insiders believe in NUVL or JANX? 97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by insiders. Comparatively, 8.1% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher earnings & valuation, NUVL or JANX? Janux Therapeutics has higher revenue and earnings than Nuvalent. Janux Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.39-18.44Janux Therapeutics$10.59M140.52-$68.99M-$1.36-18.49 Which has more risk and volatility, NUVL or JANX? Nuvalent has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.86, suggesting that its share price is 186% more volatile than the S&P 500. Does the media prefer NUVL or JANX? In the previous week, Nuvalent had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Nuvalent and 4 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.72 beat Nuvalent's score of 0.58 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend NUVL or JANX? Nuvalent currently has a consensus price target of $119.60, indicating a potential upside of 47.78%. Janux Therapeutics has a consensus price target of $91.89, indicating a potential upside of 265.36%. Given Janux Therapeutics' higher possible upside, analysts clearly believe Janux Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08 SummaryJanux Therapeutics beats Nuvalent on 8 of the 14 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.49B$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio-18.4920.8528.2620.26Price / Sales140.52303.05437.10166.10Price / CashN/A42.1137.1257.67Price / Book1.297.638.045.49Net Income-$68.99M-$55.05M$3.19B$250.45M7 Day Performance2.49%8.43%3.62%4.79%1 Month Performance1.00%8.14%5.98%9.59%1 Year Performance-43.14%1.62%29.39%16.41% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics1.9095 of 5 stars$25.15-1.8%$91.89+265.4%-43.1%$1.49B$10.59M-18.4930News CoverageAnalyst ForecastNUVLNuvalent3.3693 of 5 stars$77.93-3.2%$119.60+53.5%+2.9%$5.78BN/A-17.7540Insider TradeLNTHLantheus4.5833 of 5 stars$79.19-1.5%$130.50+64.8%-34.1%$5.56B$1.53B22.50700News CoverageTLXTelix PharmaceuticalsN/A$15.48-3.7%$22.33+44.3%N/A$5.44B$516.72M0.00N/ANews CoverageAnalyst ForecastAXSMAxsome Therapeutics4.7691 of 5 stars$107.50+2.0%$172.33+60.3%+31.6%$5.19B$385.69M-18.63380Analyst RevisionCRSPCRISPR Therapeutics3.2427 of 5 stars$51.19-1.9%$71.75+40.2%-1.9%$4.51B$37.31M-11.33460News CoverageAnalyst ForecastOptions VolumeADMAADMA Biologics3.9517 of 5 stars$17.88-2.2%$27.67+54.7%+44.8%$4.36B$426.45M21.04530Positive NewsPCVXVaxcyte1.8263 of 5 stars$32.00-3.8%$136.50+326.6%-56.4%$4.29BN/A-8.02160News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.1879 of 5 stars$66.39+0.9%$78.07+17.6%+73.3%$4.18B$130.13M-23.63140Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionCYTKCytokinetics4.0737 of 5 stars$33.36-3.8%$70.92+112.6%-33.9%$4.14B$18.47M-6.31250KRYSKrystal Biotech4.6739 of 5 stars$139.74-2.3%$211.13+51.1%-27.1%$4.13B$290.52M33.59210Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies NUVL Competitors LNTH Competitors TLX Competitors AXSM Competitors CRSP Competitors ADMA Competitors PCVX Competitors RYTM Competitors CYTK Competitors KRYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JANX Stock Alerts